SCHEMBL15391908

SCHEMBL15391908

CCCCOC(=O)N1CC(N)C(F)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
GBA2 Q9HCG7 1/20 0.38
ALDH1A1 P00352 1/20 0.38
DPP4 P27487 1/20 0.37
ATM Q13315 1/20 0.36
RIPK1 Q13546 1/20 0.35
HRH2 P25021 1/20 0.34
HRH1 P35367 1/20 0.34
TSHR P16473 2/20 0.34
HPGD P15428 1/20 0.34
GNAI3 P08754 1/20 0.34
GNAO1 P09471 1/20 0.34
GNAI1 P63096 1/20 0.34
BCHE P06276 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA4 P43681 1/20 0.34
GAA P10253 1/20 0.33
ESR1 P03372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27151384 0.89 LMNA (0.54) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL30816157 0.89 LMNA (0.54) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL29838479 0.88 SMN1; SMN2 (0.49) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL30380343 0.87 SMN1; SMN2 (0.48) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL3635383 0.87 SMN1; SMN2 (0.48) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL31463711 0.87 SMN1; SMN2 (0.48) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL30210348 0.83 LMNA (0.49) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL1542778 0.83 LMNA (0.49) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL19100768 0.82 LMNA (0.46) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL3333110 0.82 LMNA (0.54) LMNAPOLBSMN1; SMN2GBA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4028125-A1 NOVEL QUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2022-07-20 EP disclosed
EP-3844159-A1 NOVEL PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2021-07-07 EP disclosed
WO-2021048200-A1 NOVEL QUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2021-03-18 WO disclosed
EP-3759094-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES Takeda Pharmaceutical Company Limited (JP) 2021-01-06 EP disclosed
WO-2020043271-A1 NOVEL PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2020-03-05 WO disclosed
EP-3057964-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS Eisai R&D Management Co., Ltd. (JP) 2016-08-24 EP disclosed
EP-3030560-A1 BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd (CH) 2016-06-15 EP disclosed
WO-2015057659-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 WO disclosed
EP-2850060-A1 FLUORINATED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2015-03-25 EP disclosed
WO-2015019325-A1 BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2015-02-12 WO disclosed
WO-2013171694-A1 FLUORINATED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2013-11-21 WO disclosed